trending Market Intelligence /marketintelligence/en/news-insights/trending/v5fwyamd3bqc41ncpiytba2 content esgSubNav
In This List

Amicus Therapeutics director retires

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Amicus Therapeutics director retires

Amicus Therapeutics Inc. said Donald Hayden Jr. retired as a director.

The Cranbury, N.J.-based biotechnology company said Hayden had been on its board for 12 years.